Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8549679 | 0.91 | TDP1 (0.52) | LMNATDP1GAAKMT2AKMO | |
| Trifluoroacetic Acid SCHEMBL28914474 | 0.88 | KMO (0.43) | LMNATDP1GAAKMT2AKMO | |
| SCHEMBL15809138 | 0.87 | TDP1 (0.62) | LMNATDP1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL25333237 | 0.86 | TDP1 (0.56) | LMNATDP1KMOALDH1A1CYP1A2 | |
| SCHEMBL30397192 | 0.86 | LMNA (0.50) | LMNAGAAKMT2AKMOALDH1A1 | |
| SCHEMBL24189619 | 0.86 | LMNA (0.50) | LMNAGAAKMT2AKMOALDH1A1 | |
| SCHEMBL25333119 | 0.85 | ALDH1A1 (0.53) | LMNATDP1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL6142827 | 0.84 | TDP1 (0.48) | LMNATDP1GAAKMT2AALDH1A1 | |
| SCHEMBL25332266 | 0.83 | TDP1 (0.44) | TDP1KMOALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3303519 | 0.83 | ALDH1A1 (0.50) | LMNATDP1GAAKMT2AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234550-B | Aromatic formyl substituted tricyclic compound and preparation method and application thereof | 劲方医药科技(上海)股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240360154-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| CN-114920744-B | Non-covalent BTK kinase inhibitor and biological application thereof | 中国药科大学 | 2024-05-07 | — | — | CN | disclosed |
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| EP-4299575-A1 | BTK AND/OR BTK C481S SMALL MOLECULE INHIBITOR AND USE THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2024-01-03 | — | — | EP | disclosed |
| CN-115073468-B | Preparation and application of imidazopyrazines BTK inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114008042-B | Substituted pyrrolo [2,3-b ] pyridine and pyrazolo [3,4-b ] pyridine derivatives as protein kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023174300-A1 | CRYSTAL FORM OF BTK INHIBITOR, ACID SALT THEREOF, AND CRYSTAL FORM OF ACID SALT THEREOF | 劲方医药科技(上海)有限公司 | 2023-09-21 | — | — | WO | disclosed |
| CN-116768896-A | Crystal forms of BTK inhibitor, acid salt thereof and crystal forms of acid salt thereof | 劲方医药科技(上海)有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-112574200-A | Small molecule inhibitors of BTK and/or mutant C481S of BTK | 安润医药科技（苏州）有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020239124-A1 | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2020-12-03 | — | — | WO | disclosed |
| CN-111303158-A | Preparation method of (4-chloro-1H-pyrazoline [3,4-d ] pyrimidine-3-yl) aryl ketone | 成都睿智化学研究有限公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-0821665-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1090908-A2 | Cyclobutane derivatives as inhibitors of protein farnesyltransferase | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| US-5831115-A | CYCLOBUTANECARBOXAMIDES | ABBOTT LABORATORIES (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0821665-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996034851-A1 | BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | LMNA 920/4885TDP1 2526/4885GAA 37/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | LMNA 3836/4885TDP1 673/4885GAA 2940/4885 |
| US-20240360154-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | BTK, WEE1, WEE2 | LMNA 4063/4885TDP1 1557/4885GAA 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.